Soleno Therapeutics, Inc. (NASDAQ: SLNO) reported Q4 EPS of $0.80, $0.19 better than the analyst estimate of $0.61. Revenue for the quarter came in at $91.73 million versus the consensus estimate of $82.45 million.

For earnings history and earnings-related data on Soleno Therapeutics, Inc. (SLNO) click here.